Abstract 407P
Background
In Japan, the clinical utility of comprehensive genomic profiling (CGP) tests were could be conducted for treated advanced cancers in the clinical practice from 2019. However, there were no reports for young adults with advanced esophageal squamous cell carcinoma (ESCC) using the cancer genomics and advanced therapeutics in genomic profile (C-CAT) database.
Methods
We retrospectively reviewed and analyzed the CGP data on patients with advanced ESCC who were registered into the C-CAT database between 2019 and 2023. Analysis of genetic alterations (GAs) based on age, gender, and smoking history was performed, and comparisons were made between those older than 50 years (adult [A] group) and those younger than 50 (young adult [Y-A] group).
Results
Data of 850 cases with advanced ESCC were reviewed. 796 cases were in the A group and 54 cases in the Y-A group. The patients’ characteristics of A group and Y-A group were as follows, median age (range): 66 (51-87) years, 47 (29-50) years, male/female: 659/137, 28/26, smoking history yes/no/unknown: 650/125/21, 40/14/0, respectively. Oncogenic/pathogenic variants were detected in 789 cases (99.1%) in A group and 54 (100%) cases in Y-A group. There were no statistically difference in frequent actionable GAs, TP53 (94% vs. 89%, p=0.26), CDKN2A (57% vs. 56%, p=0.88, CDKN2B (45% vs. 46%, p=0.88), CCND1 (43% vs. 43%, p=0.85), FGF19 (42% vs. 41%, p=0.95), PIK3CA (41% vs. 28%, p=0.46), NFE2L2 (30% vs. 20%, p=0.21), BCL6 (14% vs. 15%, p=0.94) and EGFR (9% vs. 15%, p=0.12) between the two groups. However, EGFR amplification (amp) and mutation (mut) tend to be more detected in Y-A group with smoking history than the others (odds ratio [OR], 2.48; 95% CI, 1.05 to 5.85; p=0.03). Druggable alterations (DAs) in A group and Y-A group were detected 62% vs. 59% (p=0.94). Most frequent DAs were PIK3CA amp and mut (31%),EGFR amp and mut (9%), ERBB2 amp and mut (8%), FGFR amp and rearrangement (8%) and PTEN loss and mut (7%) in A group and PIK3CA amp and mut (28%), EGFR amp (15%), BRCA1/2 mut (7%), KRAS mut (7%) in Y-A group.
Conclusions
The current status of CGP testing for young adults with advanced ESCC in Japan is clarified.
Legal entity responsible for the study
Kazuhiro Shiraishi.
Funding
Has not received any funding.
Disclosure
S. Yamamoto: Financial Interests, Personal, Invited Speaker: Ono Pharmaceuticals, Bristol Myers Squibb, Merck Sharp & Dohme, Taiho; Financial Interests, Personal, Writing Engagements: M3, Hokuto; Financial Interests, Personal, Expert Testimony: Ono Pharmaceuticals, Hokuto. Y. Honma: Financial Interests, Personal, Advisory Board: Janssen, Rakuten Medical Japan; Financial Interests, Personal, Speaker’s Bureau: Novartis, Chugai Pharma, MSD, Ono Pharmaceutical, Bristol Myers Squibb, Merck Biopharma, Eisai, Eli Lilly, Nutri, Teijin Pharma, Bayer, Taiho Pharmaceutical; Financial Interests, Personal, Funding: Taiho Pharmaceutical, Chugai Pharma, MSD, GSK, Janssen, Adlai Nortye Biopharma, Maruho, Merck Biopharma, Genmab, Astellas Pharma, Rakuten Medical Japan, AstraZeneca. K. Kato: Financial Interests, Personal, Expert Testimony: Bristol Myers Squibb, Merck Sharp & Dohme, BeiGene, Roche, AstraZeneca, Bayer; Financial Interests, Personal, Speaker’s Bureau: Ono Pharmaceuticals, Bristol Myers Squibb, Taiho; Financial Interests, Personal, Funding: Ono Pharmaceuticals, Bristol Myers Squibb, Merck Sharp & Dohme, BeiGene, Chugai, Shionogi, AstraZeneca, Bayer. All other authors have declared no conflicts of interest.